CoreWeave Urges Approval for Core Scientific Merger, Highlights Lack of Competing Bids and Transaction Certainty
Transaction Highlights: No Bump, No Other Buyers, Board Approval Unanimous
CoreWeave is doubling down on its message to Core Scientific (CORZ) shareholders ahead of the October 30 vote: this merger represents not just a fair value exchange, but the best available outcome for stakeholders. In response to proxy advisors ISS and Glass Lewis—who both recommended voting against the deal—CoreWeave underscored that neither advisory firm disputed the strategic logic of the merger. The primary debate now centers around valuation and the future prospects of Core Scientific as a standalone entity.
The heart of CoreWeave's argument is simple but clear: Core Scientific shareholders should not expect a sweeter offer. According to CoreWeave CEO Michael Intrator, the agreed offer is final and no bid increase will occur. Glass Lewis’s report acknowledges there has been no competing bid since the initial June 2024 approach, strengthening CoreWeave's case that alternatives are, for now, nonexistent.
Merger Details: Terms and Timetable
Under the all-stock merger agreement, Core Scientific shareholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each CORZ share. Both companies’ boards have unanimously approved the deal. The expected timeline for closing is in the fourth quarter of 2025, pending regulatory and shareholder approvals.
| Key Merger Terms | Details |
|---|---|
| Exchange Ratio | 0.1235 CRWV shares for each CORZ share |
| Consideration Type | All-stock |
| Expected Closing | Q4 2025 |
| Shareholder Vote Date | October 30, 2025 |
| Competing Offers | None reported since June 2024 |
Risks of Standalone Plan Highlighted by Advisors and Management
CoreWeave points out that, while some peers have seen stock price bumps from strategic announcements, Core Scientific’s gains have already been largely realized, fueled primarily by its partnership with CoreWeave. The board’s own internal discussions—referenced in the ISS analysis—have repeatedly flagged the uncertainties of pursuing a standalone future, including competitive risks, integration complexity, and capital requirements.
Furthermore, the proxy advisors' main concerns relate to Core Scientific’s market value at the time of the vote and the future trajectory if the merger does not proceed. CoreWeave cautions shareholders to assess whether current pricing truly reflects sustainable value, or if the risk-adjusted merger path may be the prudent route.
Strategic Merits Emphasized; Proxy Advisors Question Timing and Price, Not Rationale
Importantly, neither ISS nor Glass Lewis took issue with the logic of the merger itself—they only questioned if the timing and terms maximize short-term value. CoreWeave stresses its “embedded role” in Core Scientific’s operations, which makes it a uniquely positioned acquirer, as also acknowledged by the advisors. With no other potential buyers having emerged and with regulatory clearance progressing, CoreWeave positions this deal as both strategic and, perhaps just as crucial, actionable.
Takeaway: Decision Centers on Risk and Realistic Alternatives
With the October 30 vote approaching, Core Scientific shareholders are facing a binary choice: support a deal with clear terms and near-term closure, or assume the uncertainties and risks associated with a standalone plan and an untested market for future acquirers. While questions remain about whether the offer fully captures long-term value, the immediate absence of alternatives—and a strong, unanimously approved merger agreement—suggests this deal will define Core Scientific’s next chapter.
Shareholders and observers will want to track SEC filings and final proxy statements for any late developments or updates ahead of the vote.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI